Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable CAD (coronary artery disease) defined by:~  * clinically stable for at least 3 months~ * coronary artery stenosis in any of the 3 main coronary vessels~ * or history of myocardial infarction~* Sinus rhythm at screening~* Interpretable echocardiographic images~* Age: 30 to 80 years~* Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg/m²~Exclusion Criteria:~* Ejection fraction (EF) below 30% at screening~* Progressive angina with symptoms of worsening of angina within the \<3 month~* History of recent myocardial infarction or unstable Angina~* Documented current relevant coronary stenosis ≥90% in any of the main 3 coronary vessels without bypass graft~* Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months or patients with stroke at more than 3 months~* Insulin dependent diabetes mellitus~* Clinically significant and persisting cardiac ischemia~* Atrial fibrillation, pacemaker, defibrillator, second and third degree atrial-ventricular (AV) block~* Known clinically relevant ventricular arrhythmias~* Clinically relevant heart failure with reduced left ventricular ejection fraction~* Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis; any other moderate or severe valvular failures~* Valve replacement~* Hypertrophic obstructive cardiomyopathy (HOCM)~* Previous or imminent cardiac transplantation~* Known long QT syndrome or prolongation of the QT interval with ongoing proarrhythmic conditions~* Co-medication with drugs known to have QT prolonging effect~* Intolerance of fluoroquinolones, including moxifloxacin~* History of serious adverse effects e.g. tendinitis and tendon rupture, arthralgia and effects on the peripheral and central nervous system while taking fluoroquinolones including moxifloxacin~* History of tendon diseases or tendon injury caused by quinolones~* Treatment with fluoroquinolones, including moxifloxacin during the last 2 weeks~* Treatment with organic nitrates during the last 3 months~* Treatment with riociguat during the last 3 months~* Treatment with phosphodiesterase (PDE)-5 inhibitors during the last 14 days~* Systolic blood pressure below 110 or above 160 mmHg at screening visit~* Diastolic blood pressure below 50 or above 100 mmHg at screening visit~* Heart rate below 50 or above 100 beats/min (taken from ECG measurement) at first screening visit~* Estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m\*2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment 1 (Type: EXPERIMENTAL): Treatment sequences: A\*-B-C-D
- Treatment 2 (Type: EXPERIMENTAL): Treatment sequences: D-A-B-C\*

Based on this trial design, predict the completion outcome and termination type (if applicable).